As psychedelic research moves ahead, 5-MeO-DMT is gaining recognition for its ability to treat a number of conditions.
Psychedelic medicine company Beckley Psytech is teaming up with education platform Fluence to produce first-of-its-kind professional training materials for qualified healthcare professionals to administer psychedelic-assisted psychotherapy using synthetic 5-MeO-DMT. The customizable training manual will help ensure safety and consistency in the delivery of the short-acting psychedelic medicine.
“Developing a specific psychotherapy program for 5-MeO-DMT and the training materials to deliver it are vital steps in the progression of our lead formulation’s eventual journey to market,” Fiona Dunbar, chief medical advisor for Beckley Psytech, said in a statement. “Fluence is a leader in its field when it comes to psychedelic-assisted medical training and ensuring that patients can access the benefits of psychedelic medicines with confidence and surety, and we’re excited about the new doors this strategic partnership will open.”
Psychedelic-assisted psychotherapy combines psychedelic medicine with psychotherapy. The process involves several stages, including a preparatory phase, assisting the patient through the psychedelic experience, and subsequent integration.
Beckley Psytech calls the training manual an important step toward securing clinical approval to research 5-MeO-DMT for the treatment of neuropsychiatric diseases. The company recently received authorization from drug regulators in the United Kingdome to conduct clinical trials investigating psilocybin for the treatment of a rare headache condition known as short-lasting unilaterial neuralgiform headache attacks, or SUNHA.
“Developing effective, evidence-based training for psychedelic therapy practitioners is at the heart of what we do, and we’re thrilled to be partnering with Beckley to develop a medical therapy training strategy involving 5-MeO-DMT for the very first time,” said Elizabeth Nielson, co-founder and lead trainer at Fluence.